Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Voyager Therapeut (VYGR)

Voyager Therapeut (VYGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 433,451
  • Shares Outstanding, K 37,431
  • Annual Sales, $ 104,390 K
  • Annual Income, $ -43,600 K
  • 60-Month Beta 1.79
  • Price/Sales 4.14
  • Price/Cash Flow N/A
  • Price/Book 5.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.12
  • Number of Estimates 7
  • High Estimate 2.42
  • Low Estimate -0.95
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +70.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.76 +18.65%
on 09/11/20
12.65 -8.46%
on 08/26/20
-0.90 (-7.21%)
since 08/24/20
3-Month
9.76 +18.65%
on 09/11/20
14.12 -17.99%
on 06/25/20
-1.92 (-14.22%)
since 06/24/20
52-Week
6.26 +84.98%
on 03/16/20
17.60 -34.20%
on 10/01/19
-4.86 (-29.56%)
since 09/24/19

Most Recent Stories

More News
Voyager Therapeutics Appoints Nancy Vitale to its Board of Directors

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the addition of Nancy Vitale...

VYGR : 11.58 (+0.26%)
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Michelle...

VYGR : 11.58 (+0.26%)
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease

and , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from  PD-1101, a Phase Ib open-label, three-year efficacy and safety...

NBIX : 98.86 (-0.51%)
VYGR : 11.58 (+0.26%)
Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020

New Phase 1b Data of Investigational Gene Therapy Compound, VY-AADC (NBIb-1817), Evaluating Three-Year Safety and Clinical Outcomes in Patients with Advanced Parkinson's Disease

VYGR : 11.58 (+0.26%)
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 69.33% and 77.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

VYGR : 11.58 (+0.26%)
Voyager Therapeutics: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Voyager Therapeutics Inc. (VYGR) on Monday reported a second-quarter loss of $8.7 million, after reporting a profit in the same period a year earlier.

VYGR : 11.58 (+0.26%)
Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates

Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson's disease at the Movement Disorder Society (MDS) Virtual Congress 2020

VYGR : 11.58 (+0.26%)
Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report its second quarter 2020 financial...

VYGR : 11.58 (+0.26%)
Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the termination of its...

VYGR : 11.58 (+0.26%)
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, has entered into an employment agreement...

VYGR : 11.58 (+0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade VYGR with:

Business Summary

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs...

See More

Key Turning Points

2nd Resistance Point 11.98
1st Resistance Point 11.78
Last Price 11.58
1st Support Level 11.38
2nd Support Level 11.18

See More

52-Week High 17.60
Fibonacci 61.8% 13.27
Fibonacci 50% 11.93
Last Price 11.58
Fibonacci 38.2% 10.59
52-Week Low 6.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar